Frequently Asked Questions

The preclinical toxicology record for BPC-157 is unusually quiet. Across single-dose, repeated-dose, and limit-test protocols in mice, rats, rabbits, and beagle dogs, no safety signal attributable to BPC-157 itself has been identified in any published study. The 28-day repeated-dose NOAEL in rats was established at or above 4 mg/kg/day.^[2] The 28-day repeated-dose study in beagle dogs at 10 mg/kg produced no distinct adverse effects.^[2] Genotoxicity assays (Ames test and chromosomal aberration) were negative.^[5] Embryo-fetal and teratogenicity evaluations across four species found no teratogenic effects.^[5] Anaphylaxis and injection-site toxicity assays were negative.^[5] The 2025 systematic review in HSS Journal confirmed: consistent preclinical safety profile, no adverse effects in all preclinical safety data, no clinical safety signals in limited human data.^[16]

No. At 2 grams per kilogram — administered both intravenously and by intragastric route in mice — zero mortality was observed, zero toxic effects were documented, and zero behavioral disturbances were noted.^[1] The LD50, the dose lethal to half of a test population, remains undefined for BPC-157. The LD1, the dose lethal to 1% of subjects, has also not been achieved at any tested dose in any species. This is the outcome of a formal limit test, not an absence of testing — researchers administered the maximum feasible dose and found no lethal threshold.^[1][12]

NOAEL stands for No Observed Adverse Effect Level — the highest dose tested at which no adverse effects are detected. In the 28-day repeated-dose intramuscular study in Sprague-Dawley rats, the NOAEL was established at or above 4 mg/kg/day (the highest dose tested).^[2] In the 28-day intramuscular repeated-dose study in beagle dogs, the NOAEL was established at or above 10 mg/kg.^[2] In the single-dose intramuscular tolerance study in rats, 20 mg/kg produced no adverse effects.^[2] These NOAELs are established at the ceiling of the tested range — meaning researchers could not identify a dose high enough to produce an adverse effect within those protocols.

In the toxicology protocols, liver enzymes (AST and ALT) and kidney markers remained within normal ranges throughout BPC-157 administration at all doses studied.^[2][5] A transient creatinine decrease was observed at 2 mg/kg/day in one dog protocol, which resolved completely after a two-week washout with no irreversible organ changes.^[2] In organ-protection efficacy studies — a different category — BPC-157 has been shown to normalize or prevent elevation of AST and ALT under conditions that would otherwise damage the liver: NSAID toxicity, radiation injury, and ischemia-reperfusion injury. The direction of the liver-enzyme finding in all efficacy studies is hepatoprotective — not hepatotoxic.

Based on the published preclinical safety evaluation, no. The standard genotoxicity battery — Ames test for mutagenicity, chromosomal aberration assay — returned no genotoxic findings.^[5] Embryo-fetal toxicity and teratogenicity evaluations conducted in mice, rats, rabbits, and dogs found no embryo-fetal toxicity and no teratogenic effects.^[5] No genotoxicity or teratogenicity finding has been reported in any published study.

The elimination half-life of BPC-157 is under 30 minutes in both rats and beagle dogs following intramuscular administration, based on the He et al. (2022) pharmacokinetics study.^[13] Time to maximum plasma concentration was approximately 3 minutes in rats and 6 to 9 minutes in dogs post-intramuscular injection. Pharmacokinetics were linear across all tested doses — no accumulation or saturation kinetics were observed.^[13] The compound metabolizes primarily into proline and other constituent amino acids that re-enter normal amino acid pathways. In the human intravenous infusion pilot study (20 mg IV), plasma concentrations returned to baseline within 24 hours.^[6]

At 2 grams per kilogram — the upper limit of the murine limit test — administered both intravenously and by intragastric route, zero mortality occurred, zero toxic effects were observed, and zero behavioral disturbances were noted.^[1] A limit test at 2 g/kg is the standard ceiling for acute lethal-dose evaluation in rodents. The fact that no adverse effects were observed at this dose means the LD50 and the LD1 remain undefined — the compound did not reach any toxic threshold within the tested range.

Three small human pilot datasets have been published as of 2025. The Lee and Burgess (2025) intravenous infusion pilot administered 10 mg on day one and 20 mg on day two to two healthy adults — no adverse events were documented, and comprehensive laboratory monitoring showed no clinically meaningful changes.^[6] The Lee and Padgett (2021) intra-articular knee study enrolled 17 patients with chronic knee pain — 87.5% reported significant improvement at 6 to 12 months, no adverse events were documented.^[14] A bladder instillation study for interstitial cystitis similarly reported no adverse effects.^[21] Additionally, Phase II IBD trials completed without adverse events.^[12] Zero adverse events have been reported across any published human study. The limitation is the scale of the dataset — these are pilot studies, not randomized controlled trials.

BPC-157 is not approved for any human indication by the FDA as of 2025. It is classified as an unapproved new drug. Selling or marketing it as a drug, food, or dietary supplement for human consumption is not legally permitted in the United States. Under WADA’s Prohibited List, BPC-157 is classified as a Non-Approved Substance under category S0 — a category that includes any pharmacological substance with no current approval for human therapeutic use. WADA S0 sanctions apply regardless of whether any adverse event is documented — the prohibition is based on approval status, not demonstrated harm. Athletes in any sport governed by WADA-compliant anti-doping rules face sanctions for any detectable level.

The large majority of the preclinical efficacy and safety evidence for BPC-157 was produced by the research group of Predrag Sikiric and Sven Seiwerth at the University of Zagreb over several decades.^[1] This concentration of authorship is a recognized limitation of the published record — independent replication of core findings is limited. The Jozwiak et al. (2025) systematic review in Pharmaceuticals explicitly notes potential publication bias as a concern arising from this authorship concentration.^[2] The 2025 and 2026 systematic and narrative reviews (McGuire et al., Yuan et al., Vasireddi et al.) — authored by groups independent of the Zagreb team — have engaged with this issue directly and confirmed the consistency of safety findings they could evaluate, while calling for independent large-scale trials.^[5][16][21]

The Jozwiak et al. (2025) review raised a theoretical mechanistic concern: because BPC-157 promotes angiogenesis (the formation of new blood vessels) via the VEGFR2 pathway, it could theoretically promote angiogenesis in occult malignancies if the compound were present in tumor microenvironments.^[2] No empirical evidence for this effect has been observed in any published study. It is a mechanistic inference, not an observed outcome. It is noted in this dossier because an honest reading of the literature records the full published discussion — not only the favorable data.

The Lee and Padgett (2021) intra-articular knee study found 14 of 16 evaluable patients (87.5%) reported significant pain improvement at 6 to 12 months follow-up.^[14] This is a pilot study — retrospective, uncontrolled, no placebo arm. The finding is a signal, not proof of efficacy. It cannot be distinguished from placebo effect, natural disease course, or regression to the mean without a randomized controlled trial. The safety observation — zero adverse events in 17 participants — is the more robust takeaway from this study, because the absence of adverse events is not subject to the same confounding as a subjective pain outcome.

By the standard metrics — four species evaluated, both single- and repeated-dose protocols completed, genotoxicity and teratogenicity formally evaluated, LD50 and NOAEL formally established — the BPC-157 preclinical safety package is more extensive than many research peptides, which often have only rodent single-dose data. The defined NOAEL in both rats and dogs, the formal genotoxicity battery, and the embryo-fetal toxicity evaluation in four species are not standard features of most peptide research portfolios.^[2][5] That said, none of this preclinical depth is a substitute for the completed randomized controlled trials that would establish clinical-grade safety characterization.

Every dose figure on this site describes what was administered in a published preclinical animal study or a small human pilot study — not what is recommended, suggested, or considered appropriate for human use. The language ‘studied at X µg/kg in species Y by route Z’ is the site’s consistent framing because it accurately describes what the published record contains. The site does not sell any product, it is not affiliated with any vendor or clinic, and it does not provide medical advice. It is an editorial commentary on publicly available research.